

Protecting and improving the nation's health

Progress towards ending the HIV epidemic in the United Kingdom

2018 report – appendix

About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.

Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland

Prepared by: Sophie Nash, Sarika Desai, Jameel Khawam, Nicholas Cooper, Mark McCall, Adamma Aghaizu, Sonia Rafeeq For queries relating to this document, please contact: HARSQueries@phe.gov.uk

OGL

© Crown copyright 2018

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published November 2018 PHE publications gateway number: 2018607



PHE supports the UN Sustainable Development Goals



Appendix 1: Number and proportion of likely recently acquired infections at diagnosis by exposure category and age group – England, Wales and Northern Ireland, 2017^{1,2}

| Exposure category | | 15 to 24 | 25 to 34 | 35 to 49 | 50+ | Total |
|----------------------|-------------------------------|----------|----------|----------|---------|---------|
| | Recent infections | 46 | 112 | 95 | 33 | 286 |
| | Number of samples RITA tested | 147 | 356 | 316 | 128 | 947 |
| Gay and bisexual men | % | 31% | 31% | 30% | 26% | 30% |
| | (95% C.I.) | (24-39) | (27-37) | (25-35) | (18-34) | (27-33) |
| | Recent infections | 4 | 7 | 13 | 9 | 33 |
| | Number RITA tested | 12 | 55 | 129 | 91 | 287 |
| Heterosexual men | % | 33% | 13% | 10% | 10% | 12% |
| | 95% C.I. | (10-65) | (5-24) | (5-17) | (5-18) | (8-16) |
| | Recent infections | 13 | 17 | 8 | 7 | 45 |
| | Number RITA tested | 36 | 104 | 132 | 76 | 348 |
| Heterosexual women | % | 36% | 16% | 6% | 9% | 13% |
| | 95% C.I. | (21-54) | (10-25) | (3-11) | (4-18) | (10-17) |
| | Recent infections | 17 | 24 | 21 | 16 | 78 |
| | Number RITA tested | 48 | 159 | 261 | 167 | 635 |
| All heterosexuals | % | 35% | 15% | 8% | 10% | 12% |
| | 95% C.I. | (22-51) | (10-22) | (5-12) | (5-13) | (6-15) |
| | Recent infections | 71 | 150 | 132 | 58 | 411 |
| Total | Number RITA tested | 228 | 586 | 703 | 368 | 1,885 |
| Total | % | 31% | 26% | 19% | 16% | 22% |
| | 95% C.I. | (25-38) | (22-29) | (16-22) | (12-20) | (20-24) |

¹Ascertained through the Recent Infection Testing Algorithm (RITA). ² Overall, 47% of new HIV diagnoses had a test for recent infection.

Appendix 2: List of countries where HIV prevalence is greater than 1%, 2017, UNAIDS

 * Country of birth where 10 or more people were diagnosed with HIV in the UK in 2017

Africa

Angola*, Benin, Botswana, Burundi, Cameroon*, Central African Republic, Chad, Cote d'Ivoire*, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Gabon, the Gambia, Ghana*, Guinea*, Guinea-Bissau, Kenya*, Lesotho, Liberia, Malawi*, Mali, Mozambique, Namibia, Nigeria*, Republic of the Congo*, Rwanda, Sierra Leone*, South Africa*, Swaziland, Togo, Uganda*, United Republic of Tanzania*, Zambia* and Zimbabwe*

South America

Bahamas, Barbados, Belize, Guyana, Haiti, Jamaica*, Panama, Trinidad and Tobago

Europe

Russian Federation*

Asia

Thailand*

Appendix 3: HIV testing recommendations and PHE monitoring data sources

| HIV testing recommendation | Primary guidance source(s) | Information system |
|--|--|---|
| Universal testing in specialist services | | |
| Sexual health clinics (SHS) | NICE 2016, BASHH/BHIVA/BIS 2008 | GUMCAD |
| Termination of pregnancy services | NICE 2016, BASHH/BHIVA/BIS 2008 | No data source available |
| Services for people who use drugs | NICE 2016, BASHH/BHIVA/BIS 2008 | UAM Survey of PWID |
| Specialist clinical services (TB, HCV, HBV, lymphoma ¹) | NICE 2016, HIV in Europe 2012 | ETS, SSBBV |
| Prisons | NICE 2016 | HJIPS, GUMCAD |
| Routine testing in clinical settings in areas of high and extremely higl | n prevalence (≥2 per 1,000 population 15-59 yea | rs old) |
| General practice | NICE 2016 | SSBBV |
| Secondary and emergency care | NICE 2016 | SSBBV |
| Testing at home and community settings targeting at-risk groups | · · | |
| BA communities, gay and bisexual men | NICE 2016 | GUMCAD, Annual survey |
| Self-sampling | NICE 2016 | National HIV Self-Sampling Service |
| Self-testing | WHO 2016 | Independent data source |
| 5 | IUSTI 2014 | Annual survey |
| Universal testing where there is a HIV transmission risk to others (inc | | 1000 |
| Antenatal screening | UK NSC 2006, IDPS 2016 | IDPS |
| Blood, tissue, organ donation screening | JPAC 2013 | NHSBT/PHE |
| Routine testing in high-risk groups | | |
| Those with clinical indicator diseases (including STIs, TB, HCV, HBV) | NICE 2016, HIV in Europe 2012 | SSBBV, ETS, GUMCAD |
| Sexual partners of those with known HIV | BASHH/BHIVA/SSHA/NAT 2015, WHO 2016 | GUMCAD |
| Those with history of injecting drug use | NICE 2016, WHO 2016 | UAM Survey of PWID |
| Those from country of high HIV prevalence (>1%) | NICE 2016, | GUMCAD |
| | BASHH/BHIVA/BIS 2008 | ETS |
| Sex workers | RCGP/BASHH 2013, WHO 2016 | GUMCAD |
| Transgender people | WHO 2016 | National HIV Self-Sampling Service Annual survey |
| Victims of sexual assault | RCGP/BASHH 2013 | No data source available |
| Female sexual contacts of gay and bisexual men | NICE 2016, BASHH/BHIVA/BIS 2008 | No data source available |
| Those reporting sexual contact with people from countries of high HIV prevalence | NICE 2016, BASHH/BHIVA/BIS 2008 | No data source available |

¹ No data is available for lymphoma services.

Appendix 4: Local authorities with diagnosed HIV prevalence rates above 2 per 1,000 population¹ – England, 2017

| HIV prevalence category | Upper tier local authority name | Local authority name | Residents accessing HIV related care (aged 15 to 59) | Estimated resident population in 1,000s ² (15 to 59) | Diagnosed HIV prevalence per 1,000 (aged 15 to 59) |
|-------------------------------|---|-------------------------|--|---|---|
| | City of London | City of London | 81 | 4.60 | 17.60 |
| | Lambeth | Lambeth | 3,412 | 232.97 | 14.65 |
| | Southwark | Southwark | 2,706 | 221.56 | 12.21 |
| | Kensington and Chelsea | Kensington and Chelsea | 907 | 99.81 | 9.09 |
| | Valence tegoryUpper tier local authority nameLocal authori name2City of LondonCity of LondonLambethLambethSouthwarkSouthwarkSouthwarkSouthwarkKensington and ChelseaChelseaWestminsterWestminsterLewishamLewishamBrighton and HoveBrighton and HoveCamdenCamdenHackneyIslington | Westminster | 1,450 | 165.46 | 8.76 |
| | | Lewisham | 1,693 | 202.62 | 8.36 |
| | | Brighton and Hove | 1,590 | 195.07 | 8.15 |
| | | Camden | 1,342 | 171.60 | 7.82 |
| | | Hackney | 1,498 | 192.17 | 7.80 |
| F . | Islington | Islington | 1,329 | 170.73 | 7.78 |
| 5+ | | Hammersmith and Fulham | 975 | 125.48 | 7.77 |
| | Haringey | Haringey | 1,214 | 182.53 | 6.65 |
| | Tower Hamlets | Tower Hamlets | 1,405 | 221.09 | 6.35 |
| | Greenwich | Greenwich | 1,153 | 183.33 | 6.29 |
| | Newham | Newham | 1,404 | 237.34 | 5.92 |
| | Manchester | Manchester | 2,146 | 371.27 | 5.78 |
| | 5 | _ | 742 | 128.63 | 5.77 |
| | Croydon | Croydon | 1,305 | 234.22 | 5.57 |
| | Wandsworth | Wandsworth | 1,227 | 226.23 | 5.42 |
| | Waltham Forest | Waltham Forest | 843 | 177.94 | 4.74 |
| | Salford | Salford | 733 | 155.72 | 4.71 |
| | Brent | Brent | 927 | 209.10 | 4.43 |
| | Merton | Merton | 558 | 130.62 | 4.27 |
| 240 4 00 | Blackpool | Blackpool | 321 | 78.91 | 4.07 |
| 2 10 4.99 | Luton | Luton | 529 | 130.17 | 4.06 |
| | Leicester | Leicester | 882 | 224.62 | 3.93 |
| | Hounslow | Hounslow | 628 | 169.76 | 3.70 |
| | Enfield | Enfield | 746 | 203.16 | 3.67 |
| | Ealing | Ealing | 772 | 213.85 | 3.61 |

¹ Complete list of diagnosed HIV prevalence rates available from: www.gov.uk/government/statistics/hiv-annual-data-tables. ² Population data from Office for National Statistics mid-2017 population estimate.

| HIV prevalence category | Upper tier local authority name | Local authority name | Residents accessing HIV related care (aged 15 to 59) | Estimated resident population in 1,000s ² (15 to 59) | Diagnosed HIV prevalence per 1,000 (aged 15 to 59) |
|-------------------------------|------------------------------------|-------------------------|--|---|---|
| | Reading | Reading | 368 | 104.47 | 3.52 |
| | Bournemouth | Bournemouth | 411 | 118.97 | 3.45 |
| | Slough | Slough | 313 | 91.40 | 3.42 |
| | Northamptonshire | Northampton | 461 | 135.12 | 3.41 |
| | Wolverhampton | Wolverhampton | 519 | 152.42 | 3.41 |
| | West Sussex | Crawley | 227 | 68.27 | 3.32 |
| | Nottingham | Nottingham | 716 | 220.00 | 3.25 |
| | Milton Keynes | Milton Keynes | 520 | 159.97 | 3.25 |
| | Coventry | Coventry | 736 | 228.91 | 3.22 |
| | Northamptonshire | Corby | 122 | 41.48 | 2.94 |
| | Barnet | Barnet | 696 | 236.98 | 2.94 |
| | Southend-on-Sea | Southend-on-Sea | 301 | 104.28 | 2.89 |
| | Bexley | Bexley | 408 | 145.95 | 2.80 |
| | Hertfordshire | Watford | 165 | 59.65 | 2.77 |
| | Redbridge | Redbridge | 515 | 186.54 | 2.76 |
| | Hertfordshire | Stevenage | 146 | 52.93 | 2.76 |
| | Sandwell | Sandwell | 528 | 191.76 | 2.75 |
| | Birmingham | Birmingham | 1,910 | 698.10 | 2.74 |
| | Hillingdon | Hillingdon | 503 | 186.48 | 2.70 |
| | Leeds | Leeds | 1,297 | 483.96 | 2.68 |
| | Bromley | Bromley | 500 | 192.43 | 2.60 |
| | Bedford | Bedford | 252 | 98.01 | 2.57 |
| | Bristol, City of | Bristol, City of | 763 | 299.34 | 2.55 |
| | Richmond upon Thames | Richmond upon Thames | 295 | 116.81 | 2.53 |
| | Sutton | Sutton | 307 | 122.09 | 2.51 |
| | Derby | Derby | 379 | 152.47 | 2.49 |
| | East Sussex | Hastings | 131 | 52.86 | 2.48 |
| | Southampton | Southampton | 401 | 165.05 | 2.43 |
| | East Sussex | Eastbourne | 130 | 55.06 | 2.36 |
| | Harrow | Harrow | 350 | 148.39 | 2.36 |
| | West Sussex | Worthing | 143 | 60.77 | 2.35 |
| | Northamptonshire | Wellingborough | 103 | 43.98 | 2.34 |
| | Peterborough | Peterborough | 270 | 117.39 | 2.30 |
| | Thurrock | Thurrock | 229 | 102.11 | 2.24 |
| | Hertfordshire | Hertsmere | 130 | 59.07 | 2.20 |
| | West Sussex | Adur | 75 | 34.15 | 2.20 |

| HIV prevalence category | Upper tier local authority name | Local authority name | Residents accessing HIV related care (aged 15 to 59) | Estimated resident population in 1,000s ² (15 to 59) | Diagnosed HIV prevalence per 1,000 (aged 15 to 59) |
|-------------------------------|------------------------------------|-------------------------|--|---|---|
| | East Sussex | Lewes | 117 | 53.39 | 2.19 |
| | Walsall | Walsall | 350 | 160.42 | 2.18 |
| | Norfolk | Norwich | 197 | 90.70 | 2.17 |
| | Essex | Harlow | 109 | 50.40 | 2.16 |
| | Liverpool | Liverpool | 679 | 315.48 | 2.15 |
| | Torbay | Torbay | 148 | 69.36 | 2.13 |
| | Stoke-on-Trent | Stoke-on-Trent | 318 | 149.09 | 2.13 |
| | Kingston upon Thames | Kingston upon Thames | 233 | 109.85 | 2.12 |
| | Kent | Dartford | 137 | 64.81 | 2.11 |
| | Havering | Havering | 309 | 148.37 | 2.08 |
| | Hampshire | Rushmoor | 124 | 59.63 | 2.08 |
| | Kent | Gravesham | 124 | 61.38 | 2.02 |
| | Surrey | Woking | 118 | 58.56 | 2.02 |
| | Bolton | Bolton | 330 | 164.29 | 2.01 |

Appendix 5: Estimated number of people living with HIV (diagnosed and undiagnosed) by exposure group – UK, 2017

| | Exposure category | Number diagnosed (credible interval) ¹ | Number undiagnosed (credible interval) ¹ | Total (credible interval) ¹ | % Undiagnosed (credible interval) ¹ |
|---|------------------------|--|--|--|---|
| G | ay and bisexual men | 44,700 | 4,200 | 48,900 | 9% |
| | - | (44,300, 45,100) | (2,300, 8,700) | (47,000, 53,400) | (5, 16%) |
| Р | eople who inject drugs | 2,200 | 200 | 2,500 | 10% |
| | | (2,100, 2,400) | (100, 500) | (2,300, 2,800) | (5, 18%) |
| | eterosexuals | 44,200 | 3,200 | 47,400 | 7% |
| | eterosexuais | (43,800, 44,600) | 00) (2,500, 4,900) (46,600, 49,200) | | (5, 10%) |
| | Men | 17,100 | 1,300 | 18,400 | 7% |
| | Wen | (16,800, 17,300) | (900, 2,900) | (17,900, 20,000) | (5, 15%) |
| | Black African men | 8,200 | 400 | 8,600 | 5% |
| | Black Allical men | (8,100-8,400) | (300, 500) | (8,400, 8,900) | (4, 6%) |
| | Men excluding black | 8,800 | 900 | 9,700 | 9% |
| | Africans | (8,600, 9,000) | (500, 2,500) | (9,300, 11,400) | (5, 22%) |
| | Women | 27,100 | 1,900 | 29,000 | 6% |
| | women | (26,800, 27,400) | (1,500, 2,400) | (28,500, 29,700) | (5, 8%) |
| | Black African women | 17,400 | 1,100 | 18,500 | 6% |
| | Black Allicall wollien | (17,100, 17,600) | (800, 1,500) | (18,100, 18,900) | (4, 8%) |
| | Women excluding black | 9,700 | 800 | 10,500 | 8% |
| | Africans | (9,500, 9,900) | (600, 1,200) | (10,200, 11,000) | (6, 11%) |
| | 2 | 93,800 | 7,800 | 101,600 | 8% |
| | Total ² | (93,200, 94,400) | (5,600, 12,600) | (99,300, 106,400) | (6, 12%) |

¹ Lower bound, upper bound.

² Numbers may not add to total due to rounding and inclusion of data relating to HIV acquired through mother-to-child transmission and blood related products in the total.

Appendix 6: Estimated number of people living with HIV (diagnosed and undiagnosed) by exposure group and region of residence – UK, 2017

| | | London | | | Outside London | |
|---|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| xposure | Number undiagnosed | Total | % Undiagnosed | Number undiagnosed | Total | % Undiagnosed |
| ategory | (credible interval) ¹ |
| Bay and bisexual | 1,000 (500, 2,100) | 20,300 (19,700, 21,400) | 5% (3, 10%) | 3,100 (1,500, 7,300) | 28,600 (26,900, 32,800) | 11% (5, 22%) |
| People who nject drugs | 70 (20, 200) | 800 (700, 900) | 9% | 200 (90, 400) | 1,700 (1,600, 1,900) | 10% (5, 19%) |
| leterosexuals | 900 (700, 1,300) | 16,700 (16,300, 17,200) | 5% (4, 8%) | 2,300 (1,800, 3,700) | 30,800 (30,100, 32,200) | 8% (6, 12%) |
| Men | 300 (200, 700) | 6,300 (6,000, 6,700) | 5% (4, 11%) | 900 (600, 2,300) | 12,100 (11,700, 13,500) | 8% (5, 17%) |
| Black African men | 100 (90, 200) | 3,400 (3,300, 3,500) | 4% (3, 6%) | 300 (200, 400) | 5,200 (5,100, 5,400) | 5% (4, 7%) |
| Men excluding black Africans | 200 (100, 600) | 2,800 (2,700-3,200) | 7% (3, 18%) | 700 (400, 2,000) | 6,900 (6,500, 8,200) | 10% (6, 25%) |
| Women | 500 (400, 700) | 10,400 (10,200, 10,600) | 5% (4, 6%) | 1,300 (1,000, 1,800) | 18,600 (18,200, 19,200) | 7% (6, 10%) |
| Black African women | 300 (200, 400) | 7,100 (6,900, 7,300) | 5% (4, 6%) | 700 (500, 1,100) | 11,300 (11,000, 11,800) | 6% (5, 9%) |
| Women excluding black Africans | 200 (100, 300) | 3,300 (3,200, 3,500) | 6% (4, 9%) | 600 (400, 1,000) | 7,200 (7,000, 7,600) | 8% (6, 13%) |
| Total ² | 2,000 (1,400, 3,200) | 38,600 (37,900, 39,800) | 5% (4, 8%) | 5,800 (3,800, 10,100) | 62,900 (60,900, 67,300) | 9% (6, 15%) |

¹ Lower bound, upper bound.

² Numbers may not add to total due to rounding and exclusion of data relating to HIV acquired through mother-to-child transmission and blood related products.

Appendix 7: Rates of late diagnosis (CD4 count <350 cells/mm³) by exposure group, ethnicity and gender – England, 2015 to 2017

| Exposure group | Ethnicity | Gender | Measure | London | Midlands and East of England | North of England | South of England | England total |
|----------------------|-----------|--------|------------------------------------|--------|------------------------------------|---------------------|---------------------|------------------|
| | | | Number of diagnoses with CD4 count | 2,722 | 996 | 1,106 | 952 | 5,776 |
| Gay and bisexual men | | | Number with CD4 count <350 | 670 | 376 | 410 | 327 | 1,783 |
| | | | % diagnosed late | 25% | 38% | 37% | 34% | 31% |
| | | | Number of diagnoses with CD4 count | 231 | 192 | 118 | 59 | 600 |
| | | Male | Number with CD4 count <350 | 151 | 124 | 81 | 39 | 395 |
| | Black | | % diagnosed late | 65% | 65% | 69% | 66% | 66% |
| | African | | Number of diagnoses with CD4 count | 356 | 331 | 183 | 136 | 1,006 |
| | | Female | Number with CD4 count <350 | 183 | 154 | 93 | 86 | 516 |
| | | | % diagnosed late | 51% | 47% | 51% | 63% | 51% |
| | | | Number of diagnoses with CD4 count | 163 | 215 | 198 | 233 | 809 |
| | | Male | Number with CD4 count <350 | 80 | 121 | 117 | 127 | 445 |
| Heterosexual | White | | % diagnosed late | 49% | 56% | 59% | 55% | 55% |
| contact | white | | Number of diagnoses with CD4 count | 106 | 189 | 156 | 145 | 596 |
| | | Female | Number with CD4 count <350 | 46 | 91 | 77 | 57 | 271 |
| | | | % diagnosed late | 43% | 48% | 49% | 39% | 45% |
| | | | Number of diagnoses with CD4 count | 195 | 101 | 57 | 62 | 415 |
| | | Male | Number with CD4 count <350 | 116 | 55 | 30 | 38 | 239 |
| | Other | | % diagnosed late | 59% | 54% | 53% | 61% | 58% |
| | Other | | Number of diagnoses with CD4 count | 239 | 118 | 65 | 74 | 496 |
| | | Female | Number with CD4 count <350 | 122 | 56 | 26 | 44 | 248 |
| | | | % diagnosed late | 51% | 47% | 40% | 59% | 50% |
| | | | Number of diagnoses with CD4 count | 59 | 74 | 34 | 50 | 217 |
| People who inject | drugs | | Number with CD4 count <350 | 25 | 34 | 18 | 24 | 101 |
| | | | % diagnosed late | 42% | 46% | 53% | 48% | 47% |

Appendix 8: HIV test offer, coverage and positivity – setting, gender and sexual orientation, England, 2017

a) All sexual health services

| Sexual orientation | Eligible attendees ¹ | Offere (Offered | | Tested (Coverage %) | | New Diagnoses (Positivity %) | |
|-------------------------------|------------------------------------|--------------------|------|------------------------|------|---------------------------------|-----|
| Heterosexual men | 512,327 | 459,823 | 89.8 | 393,704 | 76.8 | 412 | 0.1 |
| Gay and bisexual men | 130,617 | 120,524 | 92.3 | 116,071 | 88.9 | 1,038 | 0.9 |
| Men (total) ² | 683,010 | 599,861 | 87.8 | 527,224 | 77.2 | 1,499 | 0.3 |
| | | | | | | | |
| Heterosexual women | 996,358 | 788,731 | 79.2 | 551,773 | 55.4 | 425 | 0.1 |
| Women (total) ^{2, 3} | 1,091,709 | 826,108 | 75.7 | 578,881 | 53.0 | 450 | 0.1 |
| | | | | | | | |
| Total⁴ | 1,777,412 | 1,427,670 | 80.3 | 1,107,743 | 62.3 | 1,956 | 0.2 |

b) Specialist sexual health services⁵

| Sexual orientation | Eligible attendees ¹ | Offere (Offeree | | Test (Covera | | New diagno (Positivity | |
|-------------------------------|------------------------------------|--------------------|------|-----------------|----------|---------------------------|-----|
| Heterosexual men | 472,184 | 427,930 | 90.6 | 366,714 | 77.7 | 402 | 0.1 |
| Gay and bisexual men | 121,971 | 112,744 | 92.4 | 108,548 | 89.0 | 1,020 | 0.9 |
| Men (total) ² | 618,322 | 554,777 | 89.7 | 487,648 | 78.9 | 1,469 | 0.3 |
| | | | | | | | |
| Heterosexual women | 853,680 | 693,623 | 81.3 | 499,179 | 58.5 | 402 | 0.1 |
| Women (total) ^{2, 3} | 911,682 | 719,504 | 78.9 | 517,552 | 56.8 | 424 | 0.1 |
| | | | | | | | |
| Total⁴ | 1,532,373 | 1,275,780 | 83 | .3 1,006, | 652 65.7 | 1,900 | 0.2 |

c) SRH sexual health services (non-specialist)

| Sexual orientation | Eligible attendees ¹ | | Offered Tested (Offered %) (Coverage %) | | New diagnoses (Positivity %) | | |
|-------------------------------|------------------------------------|---------|--|--------|---------------------------------|----|-----|
| Heterosexual men | 24,572 | 20,489 | 83.4 | 15,842 | 64.5 | 9 | 0.1 |
| Gay and bisexual men | 3,673 | 3,219 | 87.6 | 2,974 | 81.0 | 18 | 0.6 |
| Men (total) ² | 34,183 | 24,859 | 72.7 | 19,644 | 57.5 | 29 | 0.1 |
| | | | | | | | |
| Heterosexual women | 108,947 | 73,423 | 67.4 | 32,004 | 29.4 | 23 | 0.1 |
| Women (total) ^{2, 3} | 123,932 | 77,569 | 62.6 | 33,522 | 27.0 | 26 | 0.1 |
| — 4 | 450.000 | | | | 00 5 | | |
| Total⁴ | 158,363 | 102,582 | 64.8 | 53,304 | 33.7 | 55 | 0.1 |

d) Other non-specialist sexual health services⁶

| Sexual orientation | Eligible attendees ¹ | Offere (Offered | | Test (Covera | | New diagnoses (Positivity %) | |
|-------------------------------|------------------------------------|--------------------|------|-----------------|------|---------------------------------|-----|
| Heterosexual men | 15,571 | 11,404 | 73.2 | 11,148 | 71.6 | 1 | 0.0 |
| Gay and bisexual men | 4,973 | 4,561 | 91.7 | 4,549 | 91.5 | 0 | 0.0 |
| Men (total) ² | 30,505 | 20,225 | 66.3 | 19,932 | 65.3 | 1 | 0.0 |
| Heterosexual women | 33,731 | 21,685 | 64.3 | 20,590 | 61.0 | 0 | 0.0 |
| Women (total) ^{2, 3} | 56,095 | 29,035 | 51.8 | 27,807 | 49.6 | 0 | 0.0 |
| Total⁴ | 86,676 | 49,308 | 56.9 | 47,787 | 55.1 | 1 | 0.0 |

¹ Eligible SHS attendee: any patient attending a SHS at least once during a calendar year; excluding those patients known to be HIV positive or for whom an HIV test was not appropriate, or for whom the attendance was reported as being and related for reproductive health care only.

² Includes those where orientation is not known.

³ Includes those who identified as women who have sex with women (WSW).

⁴ Includes those where gender is unknown/not specified.

⁵ Specialist SHS refers to level 3 sexual health services (including genitourinary medicine (GUM) and integrated GUM/sexual and reproductive health (SRH)).

⁶ This includes data submitted from other level 2 sexual health services including; young people's services, online sexual health services, enhanced GPs and other sexual health services.

Appendix 9: HIV test, coverage and positivity in eligible¹ attendees at all SHS – gender and sexual orientation, England, 2013 to 2017

| Gender and s | sexual orientation | 2013 | 2014 | 2015 | 2016 | 2017 |
|------------------------------|--------------------|-----------|-----------|-----------|-----------|-----------|
| | Tested | 395,014 | 401,787 | 401,038 | 408,430 | 393,704 |
| Heterosexual | Coverage % | 74.4 | 75.0 | 76.1 | 76.7 | 76.8 |
| men | New diagnoses | 681 | 654 | 624 | 584 | 412 |
| | Positivity % | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 |
| | | | | | | |
| | Tested | 79,598 | 93,286 | 101,612 | 106,274 | 116,071 |
| Gay and | Coverage % | 85.2 | 86.6 | 87.7 | 88.2 | 88.9 |
| bisexual men | New diagnoses | 1,718 | 1,840 | 1,733 | 1,299 | 1,038 |
| | Positivity % | 2.2 | 2 | 1.7 | 1.2 | 0.9 |
| | | | | | | |
| | Tested | 491,817 | 513,899 | 520,122 | 528,673 | 527,224 |
| Men (total) ² | Coverage % | 74.3 | 74.7 | 75.8 | 76.8 | 77.2 |
| Merr (total) | New diagnoses | 2,443 | 2,529 | 2,393 | 1,904 | 1,499 |
| | Positivity % | 0.5 | 0.5 | 0.5 | 0.4 | 0.3 |
| | | | | | | |
| | Tested | 496,414 | 521,606 | 527,305 | 550,381 | 551,773 |
| Heterosexual | Coverage % | 56.6 | 56 | 55.1 | 55.4 | 55.4 |
| women | New diagnoses | 657 | 646 | 485 | 447 | 425 |
| | Positivity % | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| | | | | | | |
| | Tested | 522,265 | 550,283 | 553,926 | 573,536 | 578,881 |
| Women (total) ^{2,3} | Coverage % | 53.1 | 52 | 51.5 | 52.6 | 53 |
| Women (total) | New diagnoses | 681 | 665 | 501 | 457 | 450 |
| | Positivity % | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| | | | | | | |
| | Tested | 1,014,241 | 1,064,343 | 1,074,244 | 1,102,681 | 1,107,743 |
| Total ⁴ | Coverage % | 61.6 | 60.9 | 61 | 61.9 | 62.3 |
| TUIAI | New diagnoses | 3,125 | 3,194 | 2,895 | 2,361 | 1,956 |
| | Positivity % | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 |

¹ Eligible SHS attendee: any patient attending a SHS at least once during a calendar year; excluding those patients known to be HIV positive or for whom an HIV test was not appropriate, or for whom the attendance was reported as being and related for reproductive health care only.

² Includes those where orientation is not known.

³ Includes those who identified as women who have sex with women (WSW).

⁴ Includes those where gender is unknown/not specified.

Appendix 10: Specialist SHS¹ meeting or exceeding BASHH HIV testing coverage guidelines² in eligible attendees³ by PHE region and sexual orientation, England, 2017

| PHE region | Number of clinics | | endees f clinics) | Gay and bise n, (% of c | | Heteros me n, (% of c | n | W | erosexual vomen of clinics) |
|----------------------|-------------------|----|----------------------|----------------------------|--------|-----------------------------|-------|----|-----------------------------------|
| East Midlands | 16 | 1 | (6%) | 15 | (94%) | 5 | (31%) | 0 | (0%) |
| East of England | 22 | 4 | (18%) | 21 | (95%) | 15 | (68%) | 4 | (18%) |
| London | 38 | 8 | (21%) | 33 | (87%) | 21 | (55%) | 5 | (13%) |
| North East | 14 | 0 | (0%) | 14 | (100%) | 3 | (21%) | 0 | (0%) |
| North West | 35 | 1 | (3%) | 29 | (83%) | 11 | (31%) | 1 | (3%) |
| South East | 33 | 3 | (9%) | 30 | (91%) | 17 | (52%) | 3 | (9%) |
| South West | 25 | 7 | (28%) | 23 | (92%) | 9 | (36%) | 5 | (20%) |
| West Midlands | 19 | 0 | (0%) | 17 | (89%) | 2 | (11%) | 0 | (0%) |
| Yorkshire and Humber | 19 | 2 | (11%) | 16 | (84%) | 8 | (42%) | 2 | (11%) |
| England | 221 | 26 | (12%) | 198 | (90%) | 91 | (41%) | 20 | (9%) |

¹ Specialist SHS refers to level 3 sexual health services (including genitourinary medicine (GUM) and integrated GUM/sexual and reproductive health (SRH)).

² Meets or exceeds 80% HIV test coverage.

³ Eligible SHS attendee (service-level analysis): any patient attending a SHS at least once during a calendar year; excluding those patients known to be HIV positive or for whom an HIV test was not appropriate, or for whom the attendance was reported as being and related for reproductive health care only.

Appendix 11: HIV test offer, test, coverage and positivity in eligible¹ gay and bisexual male attendees at Specialist SHS² – previous HIV tests England, 2017

| Attendance history & frequency of previous testing | Eligible attendees ² | Offered (Offer % | | Testec (Coverage | | New diagn (Positivity | |
|---|------------------------------------|---------------------|------|---------------------|------|--------------------------|-----|
| 4+ HIV tests in previous year ³ | 2,004 | 1,995 | 99.6 | 1,991 | 99.4 | 7 | 0.3 |
| 2-3 HIV tests in previous year ³ | 17,921 | 17,587 | 98.1 | 17,447 | 97.4 | 75 | 0.3 |
| 1 HIV test in previous year ³ | 28,590 | 26,921 | 94.2 | 26,366 | 92.2 | 99 | 0.3 |
| Last HIV test 1-2 years ago ⁴ | 11,847 | 10,947 | 92.4 | 10,498 | 88.6 | 54 | 0.5 |
| No previous HIV test | 61,609 | 55,294 | 89.7 | 52,246 | 84.8 | 785 | 3.7 |
| Total | 121,971 | 112,744 | 92.0 | 108,548 | 89.0 | 1,020 | 0.9 |

¹ Eligible SHS attendee: any patient attending a SHS at least once during a calendar year; excluding those patients known to be HIV positive or for whom an HIV test was not appropriate, or for whom the attendance was reported as being and related for reproductive health care only.

² Specialist SHS refers to level 3 sexual health services (including genitourinary medicine (GUM) and integrated GUM/sexual and reproductive health (SRH)).

³ Previous year – 43 -365 days previous to the last test in a calendar year or date of new diagnosis.

⁴ One to two years ago - at least one test in the 366-730 days and no tests in the 43-365 days previous to the last test in a calendar year or date of new diagnosis.

Appendix 12: HIV test offer, coverage and positivity in attendees at all SHS – gender, sexual orientation and age group, England, 2017

(a) Gay and bisexual men

| Age group | Eligible attendees ¹ | Offered (Offer %) | | Teste (Coverag | | New diagnoses (Positivity %) | |
|--------------------|------------------------------------|----------------------|------|-------------------|------|---------------------------------|-----|
| 15-24 | 29,843 | 27,691 | 92.8 | 26,719 | 89.5 | 189 | 0.7 |
| 25-24 | 50,750 | 47,379 | 93.4 | 45,846 | 90.3 | 424 | 0.9 |
| 35-49 | 34,858 | 31,882 | 91.5 | 30,614 | 87.8 | 313 | 1.0 |
| 50-64 | 12,412 | 11,124 | 89.6 | 10,580 | 85.2 | 103 | 1.0 |
| 65+ | 2,680 | 2,395 | 89.4 | 2,269 | 84.7 | 8 | 0.4 |
| Total ² | 130,617 | 120,524 | 92.3 | 116,071 | 88.9 | 1,038 | 0.9 |

(b) Heterosexual men

| Age group | Eligible attendees ¹ | Offered (Offer %) | | Teste (Coverag | | New diagnoses (Positivity %) | |
|--------------------|------------------------------------|----------------------|------|-------------------|------|---------------------------------|-----|
| 15-24 | 174,327 | 155,326 | 89.1 | 129,381 | 74.2 | 37 | 0.0 |
| 25-24 | 197,704 | 180,575 | 91.3 | 157,654 | 79.7 | 89 | 0.1 |
| 35-49 | 100,886 | 90,182 | 89.4 | 78,142 | 77.5 | 182 | 0.2 |
| 50-64 | 32,447 | 28,223 | 87.0 | 24,066 | 74.2 | 92 | 0.4 |
| 65+ | 6,296 | 5,073 | 80.6 | 4,206 | 66.8 | 12 | 0.3 |
| Total ² | 512,327 | 459,823 | 89.8 | 393,704 | 76.8 | 412 | 0.1 |

(c) Heterosexual women

| Age group | Eligible attendees ¹ | Offered (Offer %) | | Tested (Coverage %) | | New diagnoses (Positivity %) | |
|--------------------|------------------------------------|----------------------|------|------------------------|------|---------------------------------|-----|
| 15-24 | 443,403 | 352,807 | 79.6 | 234,726 | 52.9 | 56 | 0.0 |
| 25-24 | 344,513 | 276,784 | 80.3 | 204,682 | 59.4 | 107 | 0.1 |
| 35-49 | 167,242 | 127,959 | 76.5 | 90,235 | 54.0 | 182 | 0.2 |
| 50-64 | 33,237 | 25,640 | 77.1 | 19,101 | 57.5 | 70 | 0.4 |
| 65+ | 2,875 | 1,883 | 65.5 | 1,408 | 49.0 | 10 | 0.7 |
| Total ² | 996,358 | 788,731 | 79.2 | 551,773 | 55.4 | 425 | 0.1 |

¹ Eligible SHS attendee: any patient attending a SHS at least once during a calendar year; excluding those patients known to be HIV positive or for whom an HIV test was not appropriate, or for whom the attendance was reported as being and related for reproductive health care only.

² Includes those aged 0-15 years and those with unknown age.

Appendix 13: HIV test offer, test, coverage and positivity in eligible heterosexual black Africans attendees at Specialist SHS¹ – previous HIV tests England, 2017

| Attendance history & frequency of previous testing | Eligible attendees ² | Offere (Offered | | Teste (Coverag | | | agnoses ivity %) |
|---|------------------------------------|--------------------|------|-------------------|------|-----|---------------------|
| 4+ HIV tests in previous year ³ | 75 | 74 | 98.7 | 74 | 98.7 | 0 | 0.0 |
| 2-3 HIV tests in previous year ³ | 2,285 | 2,217 | 97.0 | 2,161 | 94.6 | <5 | <0.2 |
| 1 HIV test in previous year ³ | 8,416 | 7,818 | 92.9 | 7,270 | 86.4 | <10 | <0.1 |
| Last HIV test 1-2 years ago ⁴ | 4,823 | 4,259 | 88.3 | 3,749 | 77.7 | <5 | <0.1 |
| No previous HIV test | 42,321 | 35,515 | 83.9 | 29,221 | 69.0 | 273 | 0.9 |
| Total | 57,920 | 49,883 | 86.1 | 42,475 | 73.3 | 283 | 0.7 |

¹ Specialist SHS refers to level 3 sexual health services (including genitourinary medicine (GUM) and integrated GUM/sexual and reproductive health (SRH)).

² Eligible SHS attendee: any patient attending a SHS at least once during a calendar year; excluding those patients known to be HIV positive or for whom an HIV test was not appropriate, or for whom the attendance was reported as being related for reproductive health care only.

³ Previous year - 43-365 days previous to the last test in a calendar year or date of new diagnosis.

⁴ One to two years ago - at least one test in the 366-730 days and no tests in the 43-365 days previous to the last test in a calendar year or date of new diagnosis.

Appendix 14: HIV test offer, coverage and positivity in eligible heterosexuals at all SHS – ethnicity and country of birth, England, 2017

| Category | Eligible attendees ¹ | Offered (Offer %) | | Tested (Coverage %) | | New diagnoses (Positivity %) | |
|--|------------------------------------|----------------------|------|------------------------|------|---------------------------------|-----|
| Black African and not born in a HPC ² | 35,766 | 30,087 | 84.7 | 25,154 | 70.3 | 69 | 0.3 |
| Black African and born in HPC ² | 31,580 | 26,941 | 85.3 | 22,877 | 72.4 | 225 | 1.0 |
| Black African (total) | 67,346 | 57,028 | 84.7 | 48,031 | 71.3 | 294 | 0.6 |
| | | | | | | | |
| Born in HPC ² and not black African | 27,507 | 23,660 | 86.0 | 19,666 | 71.5 | 70 | 0.4 |
| Born in HPC ² (total) | 59,087 | 50,601 | 85.6 | 42,543 | 72.0 | 295 | 0.7 |
| | | | | | | | |
| Black African or born HPC ² | 94,853 | 80,688 | 85.1 | 67,697 | 71.4 | 364 | 0.5 |

¹ Eligible SHS attendee: any patient attending a SHS at least once during a calendar year; excluding those patients known to be HIV positive or for whom an HIV test was not appropriate, or for whom the attendance was reported as being and related for reproductive health care only.

² HPC: High prevalence country where HIV prevalence (>1%) a full list of these countries can be found in appendix 2.

Appendix 15: HIV test offer, coverage and diagnoses in partner notified contacts attending all SHS, England, 2013 to 2017

| Year | PN contacts | Offe (Offer | | Teste (Coveraç | | Contac diagnosed | | Total New diagnoses ² | PN test ratio ³ |
|------|-------------|----------------|------|-------------------|------|---------------------|-----|-------------------------------------|-------------------------------|
| 2013 | 1,976 | 1,641 | 83.0 | 1,607 | 81.3 | 101 | 6.3 | 3,125 | 0.5 |
| 2014 | 2,171 | 1,798 | 82.8 | 1,777 | 81.9 | 98 | 5.5 | 3,194 | 0.6 |
| 2015 | 2,034 | 1,773 | 87.2 | 1,745 | 85.8 | 92 | 5.3 | 2,895 | 0.6 |
| 2016 | 2,212 | 1,896 | 85.7 | 1,861 | 84.1 | 72 | 3.9 | 2,361 | 0.8 |
| 2017 | 1,903 | 1,626 | 85.4 | 1,603 | 84.2 | 69 | 4.3 | 1,956 | 0.8 |

¹ Number of diagnoses through partner notification / number of partner notified contacts (x100).

² All new HIV diagnoses in SHS.

³ PN test ratio: number of partner notified contacts to number of new diagnoses each year.

Appendix 16: Community HIV testing providers who responded to the 2018 PHE community HIV testing survey

Actionplus Foundation, Addaction Lincolnshire, Africa Advocacy Foundation, Ambition – Sefton, BDP, BHA, Best Hope, Bournemouth Drug & Alcohol Services, CGL Gloucestershire, CGL Halton, CGL Manchester, CGL Spectrum (Hertfordshire), CGL Warrington, Cheshire East Substance Misuse Service, Derby Drug and Alcohol Recovery Service, Dhiverse, Dudley Pharmacies, Embrace Life & LGBT Links Luton, Embrace UK, Essex STaRS, GMI, HertsAid, Humankind, Inclusion Recovery, Inspire, LASS, LGBT+ Foundation, Martin Fisher Foundation, Metro, Midlands Partnership NHS Foundation Trust, NAZ, Plus Me, Positive East , Positive Health (Lincs), Recovery Nottingham, Renaissance at Drugline Lancashire, SHIP BBV, Sahir House, Shine and Mesmac, Somerset Drug and Alcohol service (Turning-Point), South Gloucestershire Drug and Alcohol Services, Spectra, Summit House Support, THT, Thames Valley Positive Support, The Brunswick Centre, The Eddystone Trust, The High Life, Trade Sexual Health and Yorkshire MESMAC

Appendix 17: Tests, reactives and reactivity in community settings – gender, sexual orientation, ethnic group, country of birth, HIV test history, age group and prevalence band, 2017

| Break | down category | Tests | Reactives | Reactivity % |
|--------------------|---------------------------|--------|-----------|--------------|
| | Cis Male | 21,594 | 96 | 0.4 |
| | Cis Female | 7,210 | 20 | 0.3 |
| Gender | Trans+ Male | 101 | 0 | 0.0 |
| Gender | Trans+ Female | 65 | <5 | <7.7 |
| | Other | 180 | 0 | 0.0 |
| | Unknown | 2,034 | <20 | <1.0 |
| | | - | | |
| | Heterosexual | 15,264 | 41 | 0.3 |
| Sexual orientation | MSM | 10,364 | 67 | 0.6 |
| Gerual offentation | WSW | 405 | 0 | 0.0 |
| | Unknown | 5,151 | 20 | 0.4 |
| | 1 | 1 | | |
| | Black African | 3,479 | 14 | 0.4 |
| | Black Caribbean | 561 | <5 | <0.9 |
| | Black Other | 559 | <5 | <0.9 |
| Ethnic group | White | 18,753 | 73 | 0.4 |
| | Asian | 2,644 | <20 | <0.8 |
| | Mixed / Other | 1,820 | 15 | 0.8 |
| | Unknown | 3,368 | 13 | 0.4 |
| | | | | |
| | UK | 11,856 | 35 | 0.3 |
| Country of birth | High prevalence country | 1,912 | 9 | 0.5 |
| | Other | 3,588 | 26 | 0.7 |
| | Unknown | 13,828 | 58 | 0.4 |
| | | 1 | | |
| | Previously tested for HIV | 11,729 | 65 | 0.6 |
| HIV test history | Never tested for HIV | 6,626 | 19 | 0.3 |
| | Unknown | 12,829 | 44 | 0.3 |
| | Under 25 years | 6,036 | 20 | 0.3 |
| Age group | 25 years and over | 22,449 | 83 | 0.3 |
| Age group | Unknown | 22,449 | 25 | 0.4 |
| | OIIKIIOWII | 2,099 | 23 | 0.9 |
| | Low | 11,463 | 52 | 0.5 |
| Local authority | High | 9,496 | 35 | 0.0 |
| prevalence band | Extremely High | 6,694 | 30 | 0.4 |
| | Unknown | 3,531 | 11 | 0.3 |
| | | 0,001 | | 0.0 |
| | Total | 31,184 | 128 | 0.4 |

Appendix 18: List of data sources and associated measures

| Data source | Description | Geographical coverage | Measures |
|---|---|---|---|
| HIV and AIDS Reporting System (HARS) | National HIV surveillance: Linked dataset of people newly diagnosed and seen for HIV care, includes the Recent Infection Testing Algorithm. | National, England, Wales and Northern Ireland (RITA) | New HIV and AIDS diagnoses, recent infection, late HIV diagnoses, 1-year mortality, people seen for HIV care, retention in HIV care, treatment coverage, virological suppression, diagnosed HIV prevalence, treatment as prevention |
| Multi-parameter Evidence Synthesis (MPES) | ayesian multi-parameter evidence synthesis model, eviewed each year to take into account changes in ata sources | | Diagnosed and undiagnosed HIV prevalence among the general population and key groups |
| CD4 back-calculation model | CD4-based Bayesian back-calculation model | England | Undiagnosed HIV prevalence and incidence among gay and bisexual men |
| Probable country of acquisition | CD4 decline model to estimate country of infection for those born abroad | National | Probable country of acquisition by exposure group |
| National Study of HIV in Pregnancy and Childhood | Data on pregnant women living with HIV and their children from the Institute of Child Health | National | Mother-to-child transmission of HIV |
| Office for National Statistics | Population data | National | UK population, mortality rates, well-being figures |
| GUMCAD STI Surveillance system | National STI surveillance: disaggregate data on diagnoses made and services provided by sexual health services | England | HIV test offer, acceptance and new diagnoses among attendees |
| Unlinked anonymous monitoring survey of people who inject drugs | Annual survey carried out in specialist drug services with a self-completed questionnaire and dried blood spot sample. | England, Wales and Northern Ireland | Self-reported uptake of HIV testing and HIV prevalence in survey responders |
| Sentinel surveillance of blood borne viruses | Laboratory surveillance of blood borne viruses testing and diagnoses | England | HIV tests and positive results in tests sent to participating laboratories |
| Health and justice indictors of performance | National surveillance of burden of disease, patient needs and the quality of health services in prisons | England | HIV test offer, acceptance and new diagnoses among new receptions and transfers |

| Data source | Description | Geographical coverage | Measures |
|---|--|-----------------------|---|
| National HIV self-sampling service | National surveillance of self-sampling testing in local authorities participating in the service | England | HIV test kits returned and reactives |
| Infectious disease in pregnancy screening | National surveillance of BBV testing in antenatal care | England | HIV test offer, acceptance and new diagnoses among women presenting to antenatal care |
| NHS Blood and Transplant / PHE | National surveillance of testing in blood, tissue and deceased organ donors | National | HIV tests and confirmed positives among donors |
| PHE community HIV testing survey | Annual survey of HIV testing in community settings | England | HIV tests and reactives by survey responders |
| Biosure | Holds regulatory approval to sell self-testing kits | England | HIV self-testing kits purchased |